Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duopharma Biotech BhdXKLS:7148 -1.54%80 3-Year EBITDA Growth Rate is 11.90% as of Jun. 2026, which is 116% above its 10-year median of 5.50. GuruFocus rates XKLS:7148 with a GF Score™ of 80/100 and a GF Value™ of RM1.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 56.37% on this metric.
During the past 12 months, Duopharma Biotech Bhd's average EBITDA Per Share Growth Rate was 20.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Duopharma Biotech Bhd was 20.20% per year. The lowest was -6.40% per year. And the median was 5.50% per year.
Duopharma Biotech Bhd (XKLS:7148) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Duopharma Biotech Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:7148 vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's 3-Year EBITDA Growth Rate falls into.
Duopharma Biotech Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.90% mean?
Duopharma Biotech Bhd (XKLS:7148) has a 3-Year EBITDA Growth Rate of 11.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Duopharma Biotech Bhd and its competitors. This is 116% above median its historical median of 5.50. According to the industry distribution chart, Duopharma Biotech Bhd ranks #353 out of 809 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Duopharma Biotech Bhd's 3-Year EBITDA Growth Rate too high?
Duopharma Biotech Bhd's current 3-Year EBITDA Growth Rate of 11.90% is 116% above median its 10-year median of 5.50. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Duopharma Biotech Bhd's value of 11.90% is 33.7% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #353 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #353 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Duopharma Biotech Bhd's value of 11.90% is 33.7% above this benchmark. While the company's 10-year median is 5.50 vs. the industry median of 8.90, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current 3-Year EBITDA Growth Rate of 11.90% is 33.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current 3-Year EBITDA Growth Rate is 11.90%, which is 116% above median its own 10-year median of 5.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.50, compared to a current price of RM1.28 — trading 14.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.90%, which is 116% above median its 10-year median of 5.50 and 33.7% above the Drug Manufacturers industry median of 8.90. Duopharma Biotech Bhd's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current 3-Year EBITDA Growth Rate is 11.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.28 is trading 14.7% below its estimated GF Value™ of RM1.50.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
3-Year EBITDA Growth Rate: 11.90% (116% above median its 10-year median of 5.50)
GF Value™: RM1.50 vs. price of RM1.28 (14.7% below fair value)
Industry Position: 33.7% above the Drug Manufacturers median (#353 of 809)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
80GF Score
Get the complete analysis for XKLS:7148
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
